| Presentation Title | Conference | Date |
| Clinical evaluation of a novel oncolytic immunotherapy agent, CAVATAK® in combination with immune checkpoint therapy in advanced cancer patients | 2018 International Oncolytic Virus Conference (IOVC) – 11th Meeting, Oxford, United Kingdom | 10 April 2018
|
Extended Investor Presentation* – January 2018
* Investor Presentation supplemented with previously released clinical and scientific information